Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus lenvatinib as neoadjuvant therapy for resectable acral and mucosal melanoma
ChiCTR2500112240Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and lenvatinib in acral lentiginous melanoma (ALM) and mucosal melanoma (MM), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Major pathological response. Started Nov 2025; status: recruiting.
02
Drugs
QL1706lenvatinib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2500112240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112240.